AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05368129 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon dilation
Description: Balloon dilation was performed after DES implantation.
Study NCT05188183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M1 anodal home-based tDCS
Description: During tDCS, low amplitude direct currents are applied via scalp electrodes and penetrate the skull to enter the brain. Direct current will be transferred by a saline-soaked pair of surface sponge electrodes (35 cm2) and delivered by a specially developed, battery-driven, constant current stimulator with a maximum output of 10 mA.
Study NCT05188183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Somatosensory Training
Description: The somatosensory training will be performed during the self-administration of tDCS, including 20 sessions over 4 weeks. Sessions will start with relaxation exercises using a body scan technique, whereby subjects in a relaxed state will be instructed to sequentially interchange their mind to different regions of the body while perceiving it and establishing contact with the body part. Subjects will be asked to concentrate on any feeling (kinetic, kinesthetic or exteroceptive) related to each body part. Phantom exercises will involve the use of imagined movements of the phantom limb. Therefore, patients will be asked to perform general exercises with their phantom limb. Exercises will include hip, knee, ankle, and toe movements.
Study NCT05188183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care includes pharmacological treatments, physical therapy, occupational therapy and/or behavioral therapy that the subject is receiving.
Study NCT04588441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Description: Adenosine will be given like an inhaled asthma medication two times daily for one week (7 days). Treatment consists of 9 mg adenosine in 5ml normal saline (NS) administered over 5-10 min via an Aerogen™ nebulizer.
Study NCT05491239 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural analgesia
Description: After correct placement of the epidural catheter, a local anaesthetic (ropivacaine, levobupivacaine or bupivacaine) will be started and, according to in house protocols, an opioid will be added to the epidural solution. A provisional stop of the administration of the epidural infusion is planned after 48 hours (on the second postoperative day).
Study NCT05491239 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous regional paravertebral block
Description: The PVB catheter is placed under general anaesthesia at the beginning of the VATS procedure under direct thoracoscopic vision. The level of the PVB catheter placement is chosen at the intercostal space of the largest incision (mostly thoracic level 4 or 5). Under direct thoracoscopic vision, the surgeon inserts a Touhy needle. The tip of the needle is observed beneath the pleural surface thoracoscopically. Injection of about 2 mL ropivacaine 7.5mg/mL will create subpleural hydrodissection to reach the adequate paravertebral plane for placement of the catheter. The PVB catheter is subsequently placed under direct thoracoscopic vision and left next to the sympathetic chain in the paravertebral space. Next, a bolus of ropivacaine (total amount 20 mL including the given amount for hydrodissection) is given through the catheter.~Postoperatively, a ropivacaine 2 mg/mL pump for continuous infusion is given with an infusion rate of 8-14 ml/hour.
Study NCT05491239 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single shot intercostal nerve block
Description: At the end of the surgery a single shot ICNB will be placed at 9 levels (thoracic level 2 to 10) with 2-3mL local anaesthetics per intercostal space under direct thoracoscopic vision. The injection site will be chosen just lateral from the sympathetic trunk. This group will have no analgesic catheters for continuous analgesia. No mobility restrictions are instructed in this group.
Study NCT04997655 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound measurement
Description: In the patient group who will undergo elective laparoscopic cholecystectomy, the diaphragmatic thickness values measured and recorded routinely at the pre-operative, post-extubation and post-operative 30th minute, at the end of inspiration and expiration, and the inspiratory amplitude in m-mode in the ultrasound measured from the right anterior axillary line subcostal area were observed as observational data. will be saved in our file.
Study NCT05760352 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eccentric bike
Description: Received eccentric cycling exercise
Study NCT05760352 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Helmet ventilation
Description: Using helmet ventilation during eccentric cycling exercise
Study NCT06390202 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: there is no intervention in this study
Study NCT06617559 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior Cruciate Ligament Reconstruction with Quadriceps Autograft
Description: The investigators will perform all-inside anterior cruciate ligament reconstruction using only the tendon portion of the quadriceps tendon (without bone fragments) in this group.
Study NCT06617559 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior Cruciate Ligament Reconstruction with Hamstring Autograft
Description: The investigators will perform all-inside anterior cruciate ligament reconstruction using the hamstring tendon as a graft in this group.
Study NCT06617767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki
Description: The Reiki group received distant Reiki application to their energy centers for 20 minutes, once a day, for 4 consecutive days, by researchers with Reiki Stage II training under the guidance of a researcher with the Usui Reiki Master \& Teacher degree.
Study NCT05185258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enstilar
Description: Topical foam
Study NCT05185258 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-vehicle
Description: Topical foam
Study NCT06324656 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: crystallized phenol + platelet rich plasma application
Description: At our pilonidal care clinic, patients will undergo a comprehensive treatment regimen starting with manual or laser hair removal to reduce hair by over 90%. For pilonidal abscesses, we will perform incision, drainage, and antibiotic therapy. Treatments will include local anesthesia with lidocaine and epinephrine, thorough disinfection with povidone-iodine, and wound irrigation. Sinuses will be treated by removing hair and curettage, followed by protective ointment application and crystallized phenol to fill the cavity, ensuring precise dosing and safety.~For enhanced healing, crystallized phenol + platelet-rich plasma application patients will receive platelet-rich plasma injections to minimize infection risk and promote tissue regeneration, all under strict sterilization to maintain cleanliness and efficacy.
Study NCT06324656 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: crystallized phenol
Description: At our pilonidal care clinic, patients will undergo a comprehensive treatment regimen starting with manual or laser hair removal to reduce hair by over 90%. For pilonidal abscesses, we will perform incision, drainage, and antibiotic therapy. Treatments will include local anesthesia with lidocaine and epinephrine, thorough disinfection with povidone-iodine, and wound irrigation. Sinuses will be treated by removing hair and curettage, followed by protective ointment application and crystallized phenol to fill the cavity, ensuring precise dosing and safety.
Study NCT06629389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol 100 mg/ml
Description: The following dose regime for the 4 treatment arms will be used:~DOSE TITRATION PERIOD:~First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The first 7 days dose will be reduced to 0.5 mL/day; on subsequent 7 days, dose will be reduced to 0.3 mL/day. If a patient has reached a maximum tolerated dose, dose reduction will be made at the discretion of the investigator.
Study NCT06629389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cannabidiol 300 mg/ml
Description: The following dose regime for the 4 treatment arms will be used:~DOSE TITRATION PERIOD:~First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The first 7 days dose will be reduced to 0.5 mL/day; on subsequent 7 days, dose will be reduced to 0.3 mL/day. If a patient has reached a maximum tolerated dose, dose reduction will be made at the discretion of the investigator.
Study NCT06629389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol 400 mg/ml
Description: The following dose regime for the 4 treatment arms will be used:~DOSE TITRATION PERIOD:~First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The first 7 days dose will be reduced to 0.5 mL/day; on subsequent 7 days, dose will be reduced to 0.3 mL/day. If a patient has reached a maximum tolerated dose, dose reduction will be made at the discretion of the investigator.
Study NCT05528640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Health Literacy Program
Description: Six educational sessions will be delivered on a private YouTube channel which consists of information about mental health literacy (knowledge about priority mental illnesses, attitude/ stigma related to mental illnesses, and help-seeking efficacy). There will be six-weeks unrestricted access period. Afterwards, the round-up session which consists of problem-based learning and group sharing will be delivered in person. Two vignettes based on the clinical scenarios will be given for discussion. Furthermore, participants are encouraged to share their opinion on mental health literacy, strategies for dealing with difficulties of caring for patients with mental illnesses in general hospitals, way to promote mental health literacy of healthcare professionals in general hospitals
Study NCT04764630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Four naloxone nasal spray doses (1 every 2.5 min)
Description: Four 4 mg IN naloxone doses (left nostril at 0 min, right nostril at 2.5 min, left nostril at 5 min, right nostril at 7.5 min
Study NCT04764630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Four naloxone nasal spray doses (2 every 2.5 min)
Description: Four 4 mg IN naloxone doses (left and right nostrils at 0 min, left and right nostrils at 2.5 min)
Study NCT04764630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Two naloxone nasal spray doses (1 every 2.5 min)
Description: Two 4 mg IN naloxone doses (left nostril at 0 min, right nostril at 2.5 min)
Study NCT06629389 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The following dose regime for the 4 treatment arms will be used:~DOSE TITRATION PERIOD:~First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The first 7 days dose will be reduced to 0.5 mL/day; on subsequent 7 days, dose will be reduced to 0.3 mL/day. If a patient has reached a maximum tolerated dose, dose reduction will be made at the discretion of the investigator.
Study NCT05036824 — intervention group
Intervention type: DRUG
Intervention: tinzaparin
Description: Daily tinzaparin administration: 8000 - 14000 Anti-Xa IU
Study NCT05789758 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: Administered as specified in the treatment arm.
Study NCT04762940 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic
Description: The Amadeo® Manual Robotic System (Tyromotion GmbH, Graz, Austria) is designed for rehabilitative treatment of the hand and fingers providing robot-assisted exercise for the finger flexors and extensors. This system has a controlled position, active, active-assisted and passive exercise mode, it also allows isometric exercises with visual feedback provided during computerized games that emphasize flexion and extension.~Robotic treatment will be conducted three times a week with 24 sessions (a month and a half of treatment) with assisted therapy: It allows to carry out the movement by force of the fingers themselves, compensating the range of movement that the user does not perform; and interactive therapy: it allows to carry out active finger movement oriented to tasks or games. These can be configured to adapt them as much as possible to the capabilities of the user.
Study NCT04762940 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic
Description: The Amadeo® Manual Robotic System (Tyromotion GmbH, Graz, Austria) is designed for rehabilitative treatment of the hand and fingers providing robot-assisted exercise for the finger flexors and extensors. This system has a controlled position, active, active-assisted and passive exercise mode, it also allows isometric exercises with visual feedback provided during computerized games that emphasize flexion and extension.~Robotic treatment will be conducted three times a week with 24 sessions (a month and a half of treatment) with assisted therapy: It allows to carry out the movement by force of the fingers themselves, compensating the range of movement that the user does not perform; and interactive therapy: it allows to carry out active finger movement oriented to tasks or games. These can be configured to adapt them as much as possible to the capabilities of the user.
Study NCT04762940 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration
Description: Vibration duration of approximately 20 minutes with a high vibration frequency will be conducted prior to robotic treatment. The intensity and timing of this treatment has been based on previous protocols, as previously justified in this project. Vibration therapy, with proprioceptive stimuli through sensors placed on the distal phalanges of the fingers, modulation from lower to higher frequency being possible (high frequency vibration of 300 Hz).
Study NCT04792879 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Peripheral veins Doppler ultrasound
Description: Patients undergoing a right heart catheterization for PH diagnosis or annual follow-up in the cardiological unit of the university hospital of Poitiers will be included. A venous Doppler ultrasound will be performed by a vascular physician, with experience in vascular ultrasound imaging, within 4 hours before the right heart catheterization. Morphological parameters of vena cava, and velocimetric parameters of femoral, jugular and supra-hepatic veins will be assessed in order to study their correlation with right auricular pressure value.
Study NCT05116748 — intervention group
Intervention type: BIOLOGICAL
Intervention: COVID19 mRNA vaccine
Description: Administration of COVID19 mRNA vaccine
Study NCT06716736 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: socket preservation using dentine graft mixed with i-PRF
Description: surgical extraction of horizontally impacted third molar , placement of dentin graft mixed with i-PRF inside the socket , suturing
Study NCT06716736 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: socket preservation using bone allograft
Description: surgical extraction of horizontally impacted third molar , placement of bone allograft inside the socket , suturing
Study NCT06716736 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: socket preservation using collagen cone
Description: surgical extraction of horizontally impacted third molar , placement of collagen cone inside the socket , suturing
Study NCT06412770 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai chi
Description: Participants will be asked to do Tai Chi for 30 minutes three times a week
Study NCT06412770 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Tai Chi imagery
Description: Participants will be asked to do Tai Chi imagery for 30 minutes three times a week
Study NCT06412770 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: no-intervention
Description: The comparison group will be given usual care
Study NCT04951362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intranasal spray ivermectin
Description: intranasal spray of saline
Study NCT04951362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intranasal spray ivermectin
Description: intranasal spray of saline
Study NCT05344924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE+penpulimab+anlotinib vs. penpulimab+anlotinib
Description: Patients will receive TACE as needed; penpulimab 200 mg i.v. every 3 weeks(Q3W); and anlotinib 12 mg orally before breakfast,everyday(QD); continue taking for 2 weeks and stop for 1 week, that is, 3 weeks (21 days) as a course of treatment.
Study NCT06717061 — intervention group
Intervention type: PROCEDURE
Intervention: Harvesting of biological material
Description: During the sampling of biological material, the test subjects will be under general anesthesia, which is why the sampling will not mean increased pain or discomfort other than what is standard after a gallbladder operation with the peephole technique. . The sampling is not planned to be repeated, but is performed at the time when the patients perform their biliary surgery. During the sampling, centimeter-sized pieces of skin, fatty tissue, connective tissue and muscle are taken. Furthermore, serum and plasma will be collected. Two tubes of blood samples (10 ml total) are taken, centrifuged and pipetted before being frozen for later analysis. Pieces of tissue are placed in formalin before transport to the laboratory. The study form regarding the patient\&#39;s basic state of health will be filled in by the operator on the day of surgery.
Study NCT06716125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic treadmill walking plus low calorie diet
Description: this group (n =20 for the group) will administer low calorie diet for 12 weeks plus additionally administering supervised walking treadmill aerobic training for 45 minutes 3 times per week for 12 weeks).
Study NCT06716125 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: low calorie diet
Description: this group (n =20 for the group) will administer low calorie diet for 12 weeks
Study NCT06715319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCA
Description: OCA 5 mg once daily in combination with UDCA for 12 weeks and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period.
Study NCT06715319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UDCA
Description: 13\~15 mg/kg/day
Study NCT06715319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UDCA
Description: 13\~15 mg/kg/day
Study NCT06715319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once a day (QD) by mouth (PO)
Study NCT04900038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254
Description: GSK3640254 was available as 25 mg or 100 mg tablets administered orally.
Study NCT05208242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyperoncotic human albumin solution
Description: 20% human albumin solution (presented in 100ml glass bottles)
Study NCT05208242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buffered crystalloid solutions
Description: Buffered crystalloids solutions for all intravenous fluid therapy
Study NCT06514222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol and Ibuprofen. The combination of the Paracetamol and Ibuprofen will be given together every 8 hours
Description: Group 1- The patient will receive 400mg ibuprofen plus 1000mg Paracetamol simultaneously every 8 hours for two days.
Study NCT06514222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol and Ibuprofen. The combination of the Paracetamol and Ibuprofen will be given alternatively every four hours
Description: Group 2- The patient will receive 400mg ibuprofen and 1000mg Paracetamol at 4 hours in intervals for two days. With a total of 3 doses of ibuprofen and 3 doses of paracetamol per day
Study NCT06717386 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: diagonal pelvic osteotomy
Description: supraacetabular pelvic osteotomy in oblique shape
Study NCT06717334 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Low Dose CT imaging
Description: at baseline and at Year 1.
Study NCT06717334 — intervention group
Intervention type: OTHER
Intervention: blood draws
Description: at baseline and at Year 1.
Study NCT05162651 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency-management
Description: In addition to structured assessments at baseline, four, eight and twelve months, subjects randomized to the contingency-management group will receive a contingent bonus if the participants show successful abstinence at the end of weeks 4, 8 and 12.
Study NCT05162651 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: Subjects will receive structured, quantitative assessments at baseline, four, eight and twelve weeks.